by Elsevier-North-Holland Biomedical Press, distributors for the USA and Canada, Elsevier North-Holland in Amsterdam, New York, New York .
Written in English
|Statement||editors, A. Breccia, C. Rimondi, and G.E. Adams.|
|Contributions||Breccia, A., Rimondi, C., Adams, Gerald E.|
|LC Classifications||RC271.R3 R335|
|The Physical Object|
|Pagination||ix, 258 p. :|
|Number of Pages||258|
|LC Control Number||79010617|
The role of hypoxic tumor cells in resistance to radiotherapy and in suppression of immune response continues to endorse tumor hypoxia as a bona fide, yet largely untapped, drug target. Only nimorazole is used clinically as a radiosensitizer, and there is a dearth of new radiosensitizers Cited by: "Based on the summer course 'Mechanism of action of radiosenitizers of hypoxic cells in vitro and in vivo' held in Cesenatico August 21 to September 1, " Description: ix, . At the same time, the Minister of Education approved a proposal which also came from the Faculty of Pharmacy, to offer an advanced course on the topic "Radiosensitizers of Hypoxic Cells This course was subsequently approved by a special Committee of . Hypoxic cell radiosensitizers such as the nitroimidazoles were designed primarily to overcome chronic hypoxia, which is diffusion-limited hypoxia resulting from the inability of oxygen to diffuse further than about μm through respiring tissue.
The concept of hypoxic cell radiosensitizers has led to a comprehensive systematic program in basic and clinical research over the last decade. As the first topic in this chapter, the oxygen effect itself will be reviewed, and evidence for tumor hypoxia as a limiting factor . Tumor cells in a hypoxic environment may be as much as 2 to 3 times more resistant to radiation damage than those in a normal oxygen environment. Much research has been devoted to overcoming this problem including the use of high pressure oxygen tanks, blood substitutes that carry increased oxygen, hypoxic cell radiosensitizers such as. Nitroimidazoles sensitize hypoxic tumor cells by mimicking the effect of oxygen in the radiochemical process (i.e. DNA damage fixation) [15–17]. In contrast to oxygen, these radiosensitizers are not rapidly metabolized by the tumor cells and, consequently, are able to penetrate better into the tumor core to reach the hypoxic cells [18, 19]. Radiosensitizers and Biological modifiers in Radiotherapy 1. RADIOSENSITIZERS Dr. Sandeep Gedela PGIMER, Chandigarh 2. • Radiosensitivity • Relative susceptibility of cells,tissues,organs or organisms to the harmful effect of ionizing radiation • Bergonie and Tribondaeu’s law: Tissues will be more radiosensitive if: I. The cells are undifferenti.
"Proceedings of the course, Advanced topics on radiosensitizers of hypoxic cells, the second part of the NATO Advanced Study Institute on Radiosensitizers of Hypoxic Cells, held August September 7, , in Cesenatico, Italy."--Title page verso. Description: xiii, pages: . Keywords:Bioreductive drugs, cancer stem cells, epithelial to mesenchymal transition, hypoxia inducible factor, metastasis, radiosensitizers. Abstract: The heterogeneous distribution of hypoxic regions within solid tumors renders them refractive to chemo- and radio-therapies and contributes positively to tumor invasion and metastasis. the co-administration of hypoxic cell radiosensitizers,5,6 cyto-toxins that directly target hypoxic cells,3 and gene therapies that rely on the selective induction of HIF 3 Hypoxic cell radiosensitizers are most effective and clinically tolerable when delivered with a few large radiation doses. 5,6 Carefully con-. Proceedings: AACR th Annual Meeting ; April , ; New Orleans, LA Tumor hypoxia correlates radioresistance and poor clinical outcomes after radiotherapy. Radiosensitizers have been studied for a long time especially to overcome the problem of hypoxic tumor cells. Until now, however, radiosensitizers for hypoxic tumors have had only limited success in clinic.